Early-Stage Pharmaceutical Marketing Budgets

$995.00

With spending data for the commercialization of 14 brands, this report analyzes early-stage pharmaceutical marketing budgets and early-phase resource allocation for products of all sizes — including niche products with modest budgets, mid-level products balancing their expenditures, and larger brands with blockbuster hopes. Each brand’s data are presented in product profile format. The profiles break down each brand’s commercialization budgets into 10 spending categories — providing our clients with more detailed budgets than were included in previous Cutting Edge Information reports or can be found in our competitors’ reports today.

Download a benchmarking report summarySpeak to a pharmaceutical benchmarking expert

Report Details

Published: March 2007
Pages: 322 pages
Metrics: 780+ metrics
Charts/Graphics: 298 charts and tables

Top Reasons to Buy this Early-Stage Pharmaceutical Marketing Budgets Report

  • Receive (14) brand profiles for pre-clinical, Phase 1 and Phase 2 commercial spending in various categories.
  • Each brand profile provides details for the following categories:
    • commercial profile
    • clinical profile
    • early-stage commercialization spending

Some project and brand teams make a critical mistake early in their drugs’ development lifecycles – they fail to adequately prepare the market for their products.  Early-stage commercialization and market preparation deficiencies often are the result of insufficient funding rather than poor planning.

Don’t allow your product’s commercial potential to falter.  Use Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch to bolster your case for larger commercial budgets and to benchmark your marketing spends in pre-clinical development, Phase I and Phase II.

With spending data for the commercialization of 14 brands, this report analyzes early-phase resource allocation for products of all sizes – including niche products with modest budgets, mid-level products balancing their expenditures, and larger brands with blockbuster hopes.  Each brand’s data are presented in product profile format.  The profiles break down each brand’s commercialization budgets into 10 spending categories – providing our clients with more detailed budgets than were included in previous Cutting Edge Information reports or can be found in our competitors’ reports today.  The commercialization spending categories featured in this report include the following:

  • Thought leader development
  • Thought leader programs
  • Medical education
  • Medical information
  • Market research
  • Competitive intelligence
  • Pricing strategy and analysis
  • Pharmacoeconomics
  • Reimbursement

You may also be interested in CEIConnect: The Lifesciences Industry’s On-Demand Research Resource as well as our individual marketing research reports.

Excerpt from Early-Stage Pharmaceutical Marketing Budgets

Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch examines the commercialization budgets of 14 brands from the pre-clinical stage of development through Phase 2 clinical trials. The report is organized into 14 chapters, each of which is a profile of a different brand. The 14 brands are developed and marketed by a variety of companies that range from the industry’s largest pharmaceutical and biotechnology companies to small biopharmas that have yet to market their first product. Furthermore, the brands have
a variety of commercial expectations. Throughout the report, drugs
are often referred to as blockbusters, mid-level products, and small or
niche brands

Table of Contents

21           Executive Summary

29           Profiled Companies

30           Methodology and Definitions

33           Early-Stage Pharmaceutical Marketing Budgets: Three Principles for Success

39           Brand 1

40           Commercial Profile

42           Clinical Profile

44           Early-Stage Commercialization Spending

59           Brand 2

60           Commercial Profile

62           Clinical Profile

64           Early-Stage Commercialization Spending

81           Brand 3

82           Commercial Profile

84           Clinical Profile

85           Early-Stage Commercialization Spending

101         Brand 4

102         Commercial Profile

104         Clinical Profile

106         Early-Stage Commercialization Spending

123         Brand 5

124         Commercial Profile

126         Clinical Profile

127         Early-Stage Commercialization Spending

143         Brand 6

144         Commercial Profile

146         Clinical Profile

147         Early-Stage Commercialization Spending

163         Brand 7

164         Commercial Profile

166         Clinical Profile

168         Early-Stage Commercialization Spending

183         Brand 8

184         Commercial Profile

186         Clinical Profile

188         Early-Stage Commercialization Spending

203         Brand 9

204         Commercial Profile

206         Clinical Profile

208         Early-Stage Commercialization Spending

223         Brand 10

224         Commercial Profile

226         Clinical Profile

228         Early-Stage Commercialization Spending

243         Brand 11

244         Commercial Profile

246         Clinical Profile

248         Early-Stage Commercialization Spending

263         Brand 12

264         Commercial Profile

266         Clinical Profile

268         Early-Stage Commercialization Spending

283         Brand 13

284         Commercial Profile

286         Clinical Profile

288         Early-Stage Commercialization Spending

303         Brand 14

304         Commercial Profile

306         Clinical Profile

308         Early-Stage Commercialization Spending

Charts and Graphics

Executive Summary

22           Figure E.1: Brand Sizes and Therapeutic Areas

34           Figure E.2: Percentage of Early-Stage Spending by Commercial Category

35           Figure E.3: Percentage of Early-Stage Spending by Development Stage

37           Figure E.4: Average Commercial Spending by Early Development Stage

Brand 1

Commercial Profile

41           Figure 1.1: Brand 1 Dashboard

Clinical Profile

43           Figure 1.2: Brand 1 Development Timeline

Early-Stage Commercialization Spending

44           Figure 1.3: Brand 1: Total Commercial Spending by Development Phase

45           Table 1.1: Brand 1 Early-Stage Commercial Investments

46           Figure 1.4: Brand 1: Total Medical Affairs Spending by Development Phase

47           Figure 1.5: Brand 1: Thought Leader Development Spending by Development Phase

47           Figure 1.6: Brand 1: Thought Leader Programs & Activities Spending by

Development Phase

48           Figure 1.7: Brand 1: Medical Education Spending by Development Phase

48           Figure 1.8: Brand 1: Medical Information Spending by Development Phase

49           Figure 1.9: Brand 1: Total Decision Support Spending by Development Phase

50           Figure 1.10: Brand 1: Market Research Spending by Development Phase

50           Figure 1.11: Brand 1: Competitive Intelligence Spending by Development Phase

51           Figure 1.12: Brand 1: Total Market Access Spending by Development Phase

52           Figure 1.13: Brand 1: Pricing Strategy & Analysis Spending by Development Phase

52           Figure 1.14: Brand 1: Pharmacoeconomics Spending by Development Phase

53           Figure 1.15: Brand 1: Reimbursement Spending by Development Phase

54           Figure 1.16: Brand 1: Total Advertising & Promotions Spending by Development Phase

55           Figure 1.17: Brand 1: Pre-Clinical Spending by Commercial Category

 

56           Figure 1.18: Brand 1: Phase 1 Spending by Commercial Category

56           Figure 1.19: Brand 1: Phase 2 Spending by Commercial Category

57           Figure 1.20: Brand 1: Early-Stage Total Spending by Commercial

Brand 2

Commercial Profile

61           Figure 2.1: Brand 2 Dashboard

Clinical Profile

63           Figure 2.2: Brand 2 Development Timeline

Early-Stage Commercialization Spending

65           Figure 2.3: Brand 2: Total Commercial Spending by Development Phase

66           Table 2.1: Brand 2 Early-Stage Commercial Investments

67           Figure 2.4: Brand 2: Total Medical Affairs Spending by Development Phase

68           Figure 2.5: Brand 2: Thought Leader Development Spending by Development Phase

68           Figure 2.6: Brand 2: Thought Leader Programs & Activities Spending by

Development Phase

69           Figure 2.7: Brand 2: Medical Education Spending by Development Phase

69           Figure 2.8: Brand 2: Medical Information Spending by Development Phase

70           Figure 2.9: Brand 2: Total Decision Support Spending by Development Phase

71           Figure 2.10: Brand 2: Market Research Spending by Development Phase

71           Figure 2.11: Brand 2: Competitive Intelligence Spending by Development Phase

72           Figure 2.12: Brand 2: Total Market Access Spending by Development Phase

73           Figure 2.13: Brand 2: Pricing Strategy & Analysis Spending by Development Phase

73           Figure 2.14: Brand 2: Pharmacoeconomics Spending by Development Phase

74           Figure 2.15: Brand 2: Reimbursement Spending by Development Phase

75           Figure 2.16: Brand 2: Total Advertising & Promotions Spending by Development Phase

76           Figure 2.17: Brand 2: Pre-Clinical Spending by Commercial Category

77           Figure 2.18: Brand 2: Phase 1 Spending by Commercial Category

77           Figure 2.19: Brand 2: Phase 2 Spending by Commercial Category

78           Figure 2.20: Brand 2: Early-Stage Total Spending by Commercial Category

Brand 3

Commercial Profile

83           Figure 3.1: Brand 3 Dashboard

Clinical Profile

84           Figure 3.2: Brand 3 Development Timeline

Early-Stage Commercialization Spending

86           Figure 3.3: Brand 3: Total Commercial Spending by Development Phase

87           Table 3.1: Brand 3 Early-Stage Commercial Investments

88           Figure 3.4: Brand 3: Total Medical Affairs Spending by Development Phase

89           Figure 3.5: Brand 3: Thought Leader Development Spending by Development Phase

89           Figure 3.6: Brand 3: Thought Leader Programs & Activities Spending by

Development Phase

90           Figure 3.7: Brand 3: Medical Education Spending by Development Phase

90           Figure 3.8: Brand 3: Medical Information Spending by Development Phase

91           Figure 3.9: Brand 3: Total Decision Support Spending by Development Phase

92           Figure 3.10: Brand 3: Market Research Spending by Development Phase

92           Figure 3.11: Brand 3: Competitive Intelligence Spending by Development Phase

93           Figure 3.12: Brand 3: Total Market Access Spending by Development Phase

94           Figure 3.13: Brand 3: Pricing Strategy & Analysis Spending by Development Phase

94           Figure 3.14: Brand 3: Pharmacoeconomics Spending by Development Phase

95           Figure 3.15: Brand 3: Reimbursement Spending by Development Phase

96           Figure 3.16: Brand 3: Total Advertising & Promotions Spending by Development Phase

97           Figure 3.17: Brand 3: Pre-Clinical Spending by Commercial Category

98           Figure 3.18: Brand 3: Phase 1 Spending by Commercial Category

98           Figure 3.19: Brand 3: Phase 2 Spending by Commercial Category

99           Figure 3.20: Brand 3: Early-Stage Total Spending by Commercial Category

Brand 4

Commercial Profile

103         Figure 4.1: Brand 4 Dashboard

Clinical Profile

105         Figure 4.2: Brand 4 Development Timeline

Early-Stage Commercialization Spending

107         Figure 4.3: Brand 4: Total Commercial Spending by Development Phase

108         Table 4.1: Brand 4 Early-Stage Commercial Investments

109         Figure 4.4: Brand 4: Total Medical Affairs Spending by Development Phase

110         Figure 4.5: Brand 4: Thought Leader Development Spending by Development Phase

110         Figure 4.6: Brand 4: Thought Leader Programs & Activities Spending by

Development Phase

111         Figure 4.7: Brand 4: Medical Education Spending by Development Phase

111         Figure 4.8: Brand 4: Medical Information Spending by Development Phase

112         Figure 4.9: Brand 4: Total Decision Support Spending by Development Phase

113         Figure 4.10: Brand 4: Market Research Spending by Development Phase

113         Figure 4.11: Brand 4: Competitive Intelligence Spending by Development Phase

114         Figure 4.12: Brand 4: Total Market Access Spending by Development Phase

115         Figure 4.13: Brand 4: Pricing Strategy & Analysis Spending by Development Phase

115         Figure 4.14: Brand 4: Pharmacoeconomics Spending by Development Phase

116         Figure 4.15: Brand 4: Reimbursement Spending by Development Phase

117         Figure 4.16: Brand 4: Total Advertising & Promotions Spending by Development Phase

118         Figure 4.17: Brand 4: Pre-Clinical Spending by Commercial Category

119         Figure 4.18: Brand 4: Phase 1 Spending by Commercial Category

119         Figure 4.19: Brand 4: Phase 2 Spending by Commercial Category

120         Figure 4.20: Brand 4: Early-Stage Total Spending by Commercial Category

Brand 5

Commercial Profile

125         Figure 5.1: Brand 5 Dashboard

Clinical Profile

126         Figure 5.2: Brand 5 Development Timeline

Early-Stage Commercialization Spending

127         Figure 5.3: Brand 5: Total Commercial Spending by Development Phase

128         Table 5.1: Brand 5 Early-Stage Commercial Investments

129         Figure 5.4: Brand 5: Total Medical Affairs Spending by Development Phase

130         Figure 5.5: Brand 5: Thought Leader Development Spending by Development Phase

130         Figure 5.6: Brand 5: Thought Leader Programs & Activities Spending by

Development Phase

131         Figure 5.7: Brand 5: Medical Education Spending by Development Phase

131         Figure 5.8: Brand 5: Medical Information Spending by Development Phase

132         Figure 5.9: Brand 5: Total Decision Support Spending by Development Phase

133         Figure 5.10: Brand 5: Market Research Spending by Development Phase

133         Figure 5.11: Brand 5: Competitive Intelligence Spending by Development Phase

134         Figure 5.12: Brand 5: Total Market Access Spending by Development Phase

135         Figure 5.13: Brand 5: Pricing Strategy & Analysis Spending by Development Phase

135         Figure 5.14: Brand 5: Pharmacoeconomics Spending by Development Phase

136         Figure 5.15: Brand 5: Reimbursement Spending by Development Phase

137         Figure 5.16: Brand 5: Total Advertising & Promotions Spending by Development Phase

138         Figure 5.17: Brand 5: Pre-Clinical Spending by Commercial Category

139         Figure 5.18: Brand 5: Phase 1 Spending by Commercial Category

139         Figure 5.19: Brand 5: Phase 2 Spending by Commercial Category

140         Figure 5.20: Brand 5: Early-Stage Total Spending by Commercial Category

Brand 6

Commercial Profile

145         Figure 6.1: Brand 6 Dashboard

Clinical Profile

146         Figure 6.2: Brand 6 Development Timeline

Early-Stage Commercialization Spending

147         Figure 6.3: Brand 6: Total Commercial Spending by Development Phase

148         Table 6.1: Brand 6 Early-Stage Commercial Investments

149         Figure 6.4: Brand 6: Total Medical Affairs Spending by Development Phase

150         Figure 6.5: Brand 6: Thought Leader Development Spending by Development Phase

150         Figure 6.6: Brand 6: Thought Leader Programs & Activities Spending by

Development Phase

151         Figure 6.7: Brand 6: Medical Education Spending by Development Phase

151         Figure 6.8: Brand 6: Medical Information Spending by Development Phase

152         Figure 6.9: Brand 6: Total Decision Support Spending by Development Phase

153         Figure 6.10: Brand 6: Market Research Spending by Development Phase

153         Figure 6.11: Brand 6: Competitive Intelligence Spending by Development Phase

154         Figure 6.12: Brand 6: Total Market Access Spending by Development Phase

155         Figure 6.13: Brand 6: Pricing Strategy & Analysis Spending by Development Phase

155         Figure 6.14: Brand 6: Pharmacoeconomics Spending by Development Phase

156         Figure 6.15: Brand 6: Reimbursement Spending by Development Phase

157         Figure 6.16: Brand 6: Total Advertising & Promotions Spending by Development Phase

158         Figure 6.17: Brand 6: Pre-Clinical Spending by Commercial Category

159         Figure 6.18: Brand 6: Phase 1 Spending by Commercial Category

159         Figure 6.19: Brand 6: Phase 2 Spending by Commercial Category

160         Figure 6.20: Brand 6: Early-Stage Total Spending by Commercial Category

Brand 7

Commercial Profile

165         Figure 7.1: Brand 7 Dashboard

Clinical Profile

167         Figure 7.2: Brand 7 Development Timeline

Early-Stage Commercialization Spending

168         Figure 7.3: Brand 7: Total Commercial Spending by Development Phase

169         Table 7.1: Brand 7 Early-Stage Commercial Investments

170         Figure 7.4: Brand 7: Total Medical Affairs Spending by Development Phase

171         Figure 7.5: Brand 7: Thought Leader Development Spending by Development Phase

171         Figure 7.6: Brand 7: Thought Leader Programs & Activities Spending by

Development Phase

172         Figure 7.7: Brand 7: Medical Education Spending by Development Phase

172         Figure 7.8: Brand 7: Medical Information Spending by Development Phase

173         Figure 7.9: Brand 7: Total Decision Support Spending by Development Phase

174         Figure 7.10: Brand 7: Market Research Spending by Development Phase

174         Figure 7.11: Brand 7: Competitive Intelligence Spending by Development Phase

175         Figure 7.12: Brand 7: Total Market Access Spending by Development Phase

176         Figure 7.13: Brand 7: Pricing Strategy & Analysis Spending by Development Phase

176         Figure 7.14: Brand 7: Pharmacoeconomics Spending by Development Phase

177         Figure 7.15: Brand 7: Reimbursement Spending by Development Phase

178         Figure 7.16: Brand 7: Total Advertising & Promotions Spending by Development Phase

179         Figure 7.17: Brand 7: Pre-Clinical Spending by Commercial Category

180         Figure 7.18: Brand 7: Phase 1 Spending by Commercial Category

180         Figure 7.19: Brand 7: Phase 2 Spending by Commercial Category

181         Figure 7.20: Brand 7: Early-Stage Total Spending by Commercial Category

Brand 8

Commercial Profile

185         Figure 8.1: Brand 8 Dashboard

Clinical Profile

187         Figure 8.2: Brand 8 Development Timeline

Early-Stage Commercialization Spending

188         Figure 8.3: Brand 8: Total Commercial Spending by Development Phase

189         Table 8.1: Brand 8 Early-Stage Commercial Investments

190         Figure 8.4: Brand 8: Total Medical Affairs Spending by Development Phase

191         Figure 8.5: Brand 8: Thought Leader Development Spending by Development Phase

191         Figure 8.6: Brand 8: Thought Leader Programs & Activities Spending by

Development Phase

192         Figure 8.7: Brand 8: Medical Education Spending by Development Phase

192         Figure 8.8: Brand 8: Medical Information Spending by Development Phase

193         Figure 8.9: Brand 8: Total Decision Support Spending by Development Phase

194         Figure 8.10: Brand 8: Market Research Spending by Development Phase

194         Figure 8.11: Brand 8: Competitive Intelligence Spending by Development Phase

195         Figure 8.12: Brand 8: Total Market Access Spending by Development Phase

196         Figure 8.13: Brand 8: Pricing Strategy & Analysis Spending by Development Phase

196         Figure 8.14: Brand 8: Pharmacoeconomics Spending by Development Phase

197         Figure 8.15: Brand 8: Reimbursement Spending by Development Phase

198         Figure 8.16: Brand 8: Total Advertising & Promotions Spending by Development Phase

199         Figure 8.17: Brand 8: Pre-Clinical Spending by Commercial Category

200         Figure 8.18: Brand 8: Phase 1 Spending by Commercial Category

200         Figure 8.19: Brand 8: Phase 2 Spending by Commercial Category

201         Figure 8.20: Brand 8: Early-Stage Total Spending by Commercial Category

Brand 9

Commercial Profile

205         Figure 9.1: Brand 9 Dashboard

Clinical Profile

207         Figure 9.2: Brand 9 Development Timeline

Early-Stage Commercialization Spending

208         Figure 9.3: Brand 9: Total Commercial Spending by Development Phase

209         Table 9.1: Brand 9 Early-Stage Commercial Investments

210         Figure 9.4: Brand 9: Total Medical Affairs Spending by Development Phase

211         Figure 9.5: Brand 9: Thought Leader Development Spending by Development Phase

211         Figure 9.6: Brand 9: Thought Leader Programs & Activities Spending by

Development Phase

212         Figure 9.7: Brand 9: Medical Education Spending by Development Phase

212         Figure 9.8: Brand 9: Medical Information Spending by Development Phase

213         Figure 9.9: Brand 9: Total Decision Support Spending by Development Phase

214         Figure 9.10: Brand 9: Market Research Spending by Development Phase

214         Figure 9.11: Brand 9: Competitive Intelligence Spending by Development Phase

215         Figure 9.12: Brand 9: Total Market Access Spending by Development Phase

216         Figure 9.13: Brand 9: Pricing Strategy & Analysis Spending by Development Phase

216         Figure 9.14: Brand 9: Pharmacoeconomics Spending by Development Phase

217         Figure 9.15: Brand 9: Reimbursement Spending by Development Phase

218         Figure 9.16: Brand 9: Total Advertising & Promotions Spending by Development Phase

219         Figure 9.17: Brand 9: Pre-Clinical Spending by Commercial Category

220         Figure 9.18: Brand 9: Phase 1 Spending by Commercial Category

220         Figure 9.19: Brand 9: Phase 2 Spending by Commercial Category

221         Figure 9.20: Brand 9: Early-Stage Total Spending by Commercial Category

Brand 10

Commercial Profile

225         Figure 10.1: Brand 10 Dashboard

Clinical Profile

227         Figure 10.2: Brand 10 Development Timeline

Early-Stage Commercialization Spending

228         Figure 10.3: Brand 10: Total Commercial Spending by Development Phase

229         Table 10.1: Brand 10 Early-Stage Commercial Investments

230         Figure 10.4: Brand 10: Total Medical Affairs Spending by Development Phase

231         Figure 10.5: Brand 10: Thought Leader Development Spending by Development Phase

231         Figure 10.6: Brand 10: Thought Leader Programs & Activities Spending by

Development Phase

232         Figure 10.7: Brand 10: Medical Education Spending by Development Phase

232         Figure 10.8: Brand 10: Medical Information Spending by Development Phase

233         Figure 10.9: Brand 10: Total Decision Support Spending by Development Phase

234         Figure 10.10: Brand 10: Market Research Spending by Development Phase

234         Figure 10.11: Brand 10: Competitive Intelligence Spending by Development Phase

235         Figure 10.12: Brand 10: Total Market Access Spending by Development Phase

236         Figure 10.13: Brand 10: Pricing Strategy & Analysis Spending by Development Phase

236         Figure 10.14: Brand 10: Pharmacoeconomics Spending by Development Phase

237         Figure 10.15: Brand 10: Reimbursement Spending by Development Phase

238         Figure 10.16: Brand 10: Total Advertising & Promotions Spending by Development Phase

239         Figure 10.17: Brand 10: Pre-Clinical Spending by Commercial Category

240         Figure 10.18: Brand 10: Phase 1 Spending by Commercial Category

240         Figure 10.19: Brand 10: Phase 2 Spending by Commercial Category

241         Figure 10.20: Brand 10: Early-Stage Total Spending by Commercial Category

Brand 11

Commercial Profile

245         Figure 11.1: Brand 11 Dashboard

Clinical Profile

247         Figure 11.2: Brand 11 Development Timeline

Early-Stage Commercialization Spending

248         Figure 11.3: Brand 11: Total Commercial Spending by Development Phase

249         Table 11.1: Brand 11 Early-Stage Commercial Investments

250         Figure 11.4: Brand 11: Total Medical Affairs Spending by Development Phase

251         Figure 11.5: Brand 11: Thought Leader Development Spending by Development Phase

251         Figure 11.6: Brand 11: Thought Leader Programs & Activities Spending by

Development Phase

252         Figure 11.7: Brand 11: Medical Education Spending by Development Phase

252         Figure 11.8: Brand 11: Medical Information Spending by Development Phase

253         Figure 11.9: Brand 11: Total Decision Support Spending by Development Phase

254         Figure 11.10: Brand 11: Market Research Spending by Development Phase

254         Figure 11.11: Brand 11: Competitive Intelligence Spending by Development Phase

255         Figure 11.12: Brand 11: Total Market Access Spending by Development Phase

256         Figure 11.13: Brand 11: Pricing Strategy & Analysis Spending by Development Phase

256         Figure 11.14: Brand 11: Pharmacoeconomics Spending by Development Phase

257         Figure 11.15: Brand 11: Reimbursement Spending by Development Phase

258         Figure 11.16: Brand 11: Total Advertising & Promotions Spending by Development Phase

259         Figure 11.17: Brand 11: Pre-Clinical Spending by Commercial Category

260         Figure 11.18: Brand 11: Phase 1 Spending by Commercial Category

260         Figure 11.19: Brand 11: Phase 2 Spending by Commercial Category

261          Figure 11.20: Brand 11: Early-Stage Total Spending by Commercial Category

Brand 12

Commercial Profile

265         Figure 12.1: Brand 12 Dashboard

Clinical Profile

267         Figure 12.2: Brand 12 Development Timeline

Early-Stage Commercialization Spending

268         Figure 12.3: Brand 12: Total Commercial Spending by Development Phase

269         Table 12.1: Brand 12 Early-Stage Commercial Investments

270         Figure 12.4: Brand 12: Total Medical Affairs Spending by Development Phase

271         Figure 12.5: Brand 12: Thought Leader Development Spending by Development Phase

271         Figure 12.6: Brand 12: Thought Leader Programs & Activities Spending by

Development Phase

272         Figure 12.7: Brand 12: Medical Education Spending by Development Phase

272         Figure 12.8: Brand 12: Medical Information Spending by Development Phase

273         Figure 12.9: Brand 12: Total Decision Support Spending by Development Phase

274         Figure 12.10: Brand 12: Market Research Spending by Development Phase

274         Figure 12.11: Brand 12: Competitive Intelligence Spending by Development Phase

275         Figure 12.12: Brand 12: Total Market Access Spending by Development Phase

276         Figure 12.13: Brand 12: Pricing Strategy & Analysis Spending by Development Phase

276         Figure 12.14: Brand 12: Pharmacoeconomics Spending by Development Phase

277         Figure 12.15: Brand 12: Reimbursement Spending by Development Phase

278         Figure 12.16: Brand 12: Total Advertising & Promotions Spending by Development Phase

279         Figure 12.17: Brand 12: Pre-Clinical Spending by Commercial Category

280         Figure 12.18: Brand 12: Phase 1 Spending by Commercial Category

280         Figure 12.19: Brand 12: Phase 2 Spending by Commercial Category

281         Figure 12.20: Brand 12: Early-Stage Total Spending by Commercial Category

Brand 13

Commercial Profile

285         Figure 13.1: Brand 13 Dashboard

Clinical Profile

287         Figure 13.2: Brand 13 Development Timeline

Early-Stage Commercialization Spending

288         Figure 13.3: Brand 13: Total Commercial Spending by Development Phase

289         Table 13.1: Brand 13 Early-Stage Commercial Investments

290         Figure 13.4: Brand 13: Total Medical Affairs Spending by Development Phase

291         Figure 13.5: Brand 13: Thought Leader Development Spending by Development Phase

291         Figure 13.6: Brand 13: Thought Leader Programs & Activities Spending by

Development Phase

292         Figure 13.7: Brand 13: Medical Education Spending by Development Phase

292         Figure 13.8: Brand 13: Medical Information Spending by Development Phase

293         Figure 13.9: Brand 13: Total Decision Support Spending by Development Phase

294         Figure 13.10: Brand 13: Market Research Spending by Development Phase

294         Figure 13.11: Brand 13: Competitive Intelligence Spending by Development Phase

295         Figure 13.12: Brand 13: Total Market Access Spending by Development Phase

296         Figure 13.13: Brand 13: Pricing Strategy & Analysis Spending by Development Phase

296         Figure 13.14: Brand 13: Pharmacoeconomics Spending by Development Phase

297         Figure 13.15: Brand 13: Reimbursement Spending by Development Phase

298         Figure 13.16: Brand 13: Total Advertising & Promotions Spending by Development Phase

299         Figure 13.17: Brand 13: Pre-Clinical Spending by Commercial Category

300         Figure 13.18: Brand 13: Phase 1 Spending by Commercial Category

300         Figure 13.19: Brand 13: Phase 2 Spending by Commercial Category

301         Figure 13.20: Brand 13: Early-Stage Total Spending by Commercial Category

Brand 14

Commercial Profile

305         Figure 14.1: Brand 14 Dashboard

Clinical Profile

307         Figure 14.2: Brand 14 Development Timeline

Early-Stage Commercialization Spending

308         Figure 14.3: Brand 14: Total Commercial Spending by Development Phase

309         Table 14.1: Brand 14 Early-Stage Commercial Investments

310         Figure 14.4: Brand 14: Total Medical Affairs Spending by Development Phase

311         Figure 14.5: Brand 14: Thought Leader Development Spending by Development Phase

311         Figure 14.6: Brand 14: Thought Leader Programs & Activities Spending by

Development Phase

312         Figure 14.7: Brand 14: Medical Education Spending by Development Phase

312         Figure 14.8: Brand 14: Medical Information Spending by Development Phase

313         Figure 14.9: Brand 14: Total Decision Support Spending by Development Phase

314         Figure 14.11: Brand 14: Competitive Intelligence Spending by Development Phase

314         Figure 14.10: Brand 14: Market Research Spending by Development Phase

315         Figure 14.12: Brand 14: Total Market Access Spending by Development Phase

316         Figure 14.13: Brand 14: Pricing Strategy & Analysis Spending by Development Phase

316         Figure 14.14: Brand 14: Pharmacoeconomics Spending by Development Phase

317         Figure 14.15: Brand 14: Reimbursement Spending by Development Phase

318         Figure 14.16: Brand 14: Total Advertising & Promotions Spending by Development Phase

319         Figure 14.17: Brand 14: Pre-Clinical Spending by Commercial Category

320         Figure 14.18: Brand 14: Phase 1 Spending by Commercial Category

320         Figure 14.19: Brand 14: Phase 2 Spending by Commercial Category

321         Figure 14.20: Brand 14: Early-Stage Total Spending by Commercial Category